Dr. Breit has worked in early-stage and clinical drug development for over 15 years. Prior to joining Rezolute, Dr. Breit directed numerous small and large molecule preclinical development programs for the oral, inhalation and parenteral delivery of anti-cancer compounds, drugs for the treatment of inflammatory disorders as well as vaccines. At Bend Research/Lonza Dr. Breit worked with preclinical R&D and clinical stage CMC teams at large and small pharmaceutical and biotechnology companies, advancing compounds from early preclinical development into clinical evaluation. Challenging drug development problem statements such as early-stage compound characterization and the creation of new technologies were hallmarks of his time at Bend Research. Activities included the creation of novel drug delivery platforms (nanotechnology, polymer conjugates), spray dried engineered particles as well as the development of machine learning tools to optimize antibody manufacturing.
Subsequent to working at Bend Research/Lonza, Dr. Breit worked as a consultant with various biotechnology companies in preclinical and clinical development, including Rezolute. Since joining Rezolute in 2018, Dr. Breit has focused on enabling late-stage development activities for RZ358 and RZ402; he has also led efforts focused on early-stage drug creation and development.
Dr. Breit has received industry recognition through invited lectures, publications and patents. He received his Bachelor of Science degree from UC Santa Barbara and his Ph.D. from the College of Medicine at the University of South Alabama, his NIH funded postdoctoral fellowship was conducted while at Roche Palo Alto. While at Roche his research focused on understanding genomic polymorphisms’ roles in complex disease states such as cancer, diabetes and obesity.